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Abstract: MAPK and p14ARF–MDM2–p53 pathways are critical in cutaneous melanomas.
Here, synergistic combination of the MEK inhibitor, trametinib, with MDM2 inhibitors,
nutlin-3/RG7388/HDM201, and the mechanistic basis of responses, for BRAFV600E and p53WT
melanoma cells, are reported. The combination treatments induced higher levels of p53 target gene
transcripts and protein products, resulting in increased cell cycle arrest and apoptosis compared with
MDM2 inhibitors alone, suggesting trametinib synergized with MDM2 inhibitors via upregulation
of p53-dependent pathways. In addition, DUSP6 phosphatase involvement was indicated by
downregulation of its mRNA and protein following pERK reduction by trametinib. Furthermore,
suppression of DUSP6 by siRNA, or inhibition with the small molecule inhibitor, BCI, at a dose
without cytotoxicity, potentiated the effect of MDM2 inhibitors through increased ATM-dependent
p53 phosphorylation, as demonstrated by complete reversal with the ATM inhibitor, KU55933.
Trametinib synergizes with MDM2 inhibitors through a novel DUSP6 mechanism in BRAFV600E and
p53WT melanoma cells, in which DUSP6 regulation of p53 phosphorylation is mediated by ATM.
This provides a new therapeutic rationale for combination treatments involving activation of the
ATM/p53 pathway and MAPK pathway inhibition.
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1. Introduction
Alterations of genes involving both the mitogen-activated protein kinase (MAPK)
(RAS-RAF-MEK-ERK) pathway and p14ARF–MDM2–p53 network are important in cutaneous
melanoma [1–3]. The BRAFV600E mutation occurs in 50–60% of melanomas [4,5], and small molecule kinase
inhibitors targeting BRAF and MEK have become the standard treatment for patients with inoperable
BRAFV600E melanoma [6,7]. Despite impressive response rates in the early period of treatment, eventual
relapse resulting from acquired resistance occurs for most patients. Therefore, additional therapeutic
strategies are needed, and activating p53 function could be a parallel approach for melanoma treatment [8,9].
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Mutations of p53 occur in approximately half of human cancers overall, but the frequency
of p53 mutation varies among different cancer types. For melanomas, more than 80% are p53
wild-type (p53WT). However, loss of CKDN2A, which is a negative regulator of MDM2, is frequent
in melanoma, and consequent increased MDM2 activity resulting in suppression of p53 function is
therefore likely [4,10,11]. In the subgroup of BRAF mutated melanoma, ~90% of tumors are p53WT [5].
Therefore, a therapeutic strategy of combining MAPK inhibitors and treatment reactivating p53
could have benefit in BRAFV600E/p53WT melanoma. MDM2-p53 binding antagonists stabilize p53
by preventing MDM2-mediated inhibition and degradation of p53, which leads to activation of the
p53 pathway in cancer cells retaining wild type p53, causing cell cycle arrest, apoptosis, and cell
senescence [12]. Nutlin-3 was the first generation MDM2-p53 binding antagonist to be developed and
shown to have efficacy in vitro and in vivo [13–15]. Both RG7388 (idasanutlin) [16] and HDM201 [17],
orally bioavailable examples of the new generation of MDM2-p53 binding antagonists, efficiently
suppress tumor growth in vivo, and clinical trials are currently ongoing to investigate the clinical
efficacy of these and other MDM2 inhibitors in a range of cancers.
Dual specificity phosphatase 6 (DUSP6), MAP kinase phosphatase-3 (MKP-3), a member of the
DUSP family of phosphatases, dephosphorylates phospho-ERK (pERK), and has been reported to
be regulated by p53 in HCT116 cells [18]. In addition, the MEK/ERK kinases have been reported
to positively regulate DUSP6 mRNA levels [19], and to phosphorylate and promote degradation of
DUSP6 protein [20]. Our datamining shows that melanoma cell lines express the highest level of
DUSP6 mRNA among all cancer cell lines, according to the Cancer Cell Line Encyclopedia (CCLE) [21],
and second highest among primary cancer tissues in cBioPortal (Supplementary Figure S1) [22].
Compared with BRAFWT and NRASWT melanoma, significantly higher DUSP6 expression was found
in melanoma cells with BRAF and NRAS mutations [23]. Furthermore, DUSP6 expression was found to
be a predictive biomarker for sensitivity to trametinib, and absence of DUSP6 expression was associated
with resistance to trametinib regardless of RAF/RAS status [24]. These collective observations indicate
that DUSP6 plays an important autoregulatory role connecting the MAPK pathway and MDM2/p53
networks in cancer. We therefore hypothesized that DUSP6 is involved in the response to combination
treatments targeting the MAPK and p53 pathways in BRAFV600E melanoma.
In the current study, we tested combination treatments with a MEK inhibitor, trametinib, and
MDM2 inhibitors, nutlin-3/RG7388/HDM201, in BRAFV600E/p53WT melanoma cell lines, and explored
the potential mechanism for the observed synergistic response to these combinations, revealing DUSP6
as a key connector for regulation between the MAPK and p53 pathways, and involvement of the ataxia
telangiectasia (ATM) kinase.
2. Results
2.1. Combination Treatment of MDM2 Inhibitors and Trametinib in BRAFV600E and p53WT Melanoma Cells
The effect of MDM2 inhibitors, nutlin-3/RG7388/HDM201, in combination with trametinib,
was investigated for BRAFV600E and p53WT melanoma cancer cell lines, A375 and WM35, using
median-effect analysis [25]. A375 and WM35 were treated with trametinib, nutlin-3/RG7388/HDM201
alone, or in combination, at constant ratios, for 72 h (Figure 1A–F). To quantify and test the effect of
combination treatment with MDM2 inhibitors and trametinib for synergy, the combination index (CI)
was calculated using CalcuSyn, and almost all CIs for different combinations (except nutlin-3 and
trametinib in A375) showed the combinations to be synergistic (CI < 0.9) at effective dose (ED)50-95,
the average of ED50, ED75, ED90, and ED95 (Figure 1G,H). The degree of synergy varies with compound,
dose effect level, and cell line. Generally, the CIs at ED75, ED90, and ED95 showed stronger synergistic
effects than the CIs at ED50. Also, there was a favorable dose reduction index (DRI > 1.0), indicating
the combination treatment could reduce the dose of each agent to achieve the same effects on the cells
as the individual agents used singly (Table 1).
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Figure 1. Synergistic effect of trametinib and MDM2 inhibitors on p53WT and BRAFV600E melanoma 
cells. Growth inhibition curves for trametinib, nutlin-3/RG7388/HDM201 alone or in combination at 
constant concentration ratios for 72 hours with A375 (A,C,E) and WM35 (B,D,F). The CI values for 
nutlin-3/RG7388/HDM201 in combination with trametinib at ED50, ED75, ED90 and ED50-95 (average of 
CI values at ED50, ED75, ED90, and ED95) for A375 (G) and WM35 (H). (I,J) Clonogenic survival of A375 
following RG7388 (100nM) and/or trametinib (1 nM) 72 hours treatment. SEM, standard error of the 
mean. ns, p ≥ 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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. s, 0.05; *, p < 0.05; **, p < .01; ***, p < .001.
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Table 1. Summary of dose reduction index (DRI) for the combination treatment in A375, WM35.
Cell Line
ED50 ED75 ED90
Nutlin-3 Trametinib Nutlin-3 Trametinib Nutlin-3 Trametinib
A375 1.52 ± 0.05 3.43 ± 0.86 1.63 ± 0.05 3.49 ± 0.79 1.75 ± 0.07 3.58 ± 0.74
WM35 1.66 ± 0.73 4.15 ± 1.19 7.34 ± 1.45 3.93 ± 1.12 62.1 ± 14.3 3.72 ± 1.05
RG7388 Trametinib RG7388 Trametinib RG7388 Trametinib
A375 4.84 ± 0.75 3.30 ± 0.77 18.3 ± 5.94 3.31 ± 0.71 42.6 ± 20.6 3.33 ± 0.66
WM35 0.87 ± 0.19 2.85 ± 1.12 9.24 ± 4.57 3.70 ± 0.82 61.7 ± 2.37 9.93 ± 6.71
HDM201 Trametinib HDM201 Trametinib HDM201 Trametinib
A375 2.44 ± 0.57 2.63 ± 0.48 2.97 ± 0.51 7.17 ± 2.27 3.84 ± 0.76 22.2 ± 10.1
WM35 3.23 ± 0.58 4.48 ± 0.86 2.30 ± 0.58 9.41 ± 2.06 2.41 ± 0.97 25.9 ± 9.57
ED, effective dose.
Clonogenic survival of A375 cells showed 1 nM trametinib produced no significant reduction
in colony formation as a single agent, but significantly decreased the number of colonies when
combined with RG7388 and HDM201, showing that trametinib enhanced the cytotoxic activity of
MDM2 inhibitors (Figure 1I,J, Supplementary Figure S2).
2.2. Combination of Trametinib and MDM2 Inhibitors Increased the Induction of p53 Transcriptional Targets,
Resulting in Further Cell Cycle Arrest and Apoptosis
To understand the possible mechanisms for the synergistic effect of these combinations,
immunoblotting and qRT-PCR was performed for A375 treated with trametinib (1 nM) ± nutlin-3
(1 µM)/RG7388 (0.2 µM) (Figure 2A,B) and also for WM35/WM35-R treated with trametinib (1 nM)
± RG7388 (0.2 µM) for 6 and 24 h (Figure 3A,B). The on-target effects of p53 stabilization and pERK
suppression were observed after treatment with MDM2 inhibitors and trametinib, respectively, in A375
and WM35. Interestingly, after 24-h treatment, significantly higher p21 expression was found with
combination treatment than for MDM2 inhibitors alone, without a readily observable increase of p53
protein. Expression of mRNA for the p53 transcriptional targets, CDKN1A,MDM2, BAX, TP53I3(PIG-3),
and BBC3(PUMA), was evaluated by qRT-PCR, and showed that combination treatments induced
more transcripts than MDM2 inhibitors alone, particularly after 24 h treatment (Figures 2B and 3B).
No significant increase of TP53 mRNA was found, so it was reasonable to hypothesize that trametinib
modulates post-translational modification of p53 in cells after concurrent treatment with MDM2
inhibitors. To evaluate the changes in cell cycle distribution and apoptosis after treatments with either
MDM2 inhibitors or trametinib, alone or in combination, fluorescence-activated cell sorting (FACS)
and caspase 3/7 assay were performed. FACS showed the combination treatment induced more cell
cycle arrest than single agent treatment, evidenced by decreases in S phase fractions and increases in
either G1 or G2 phases (Figure 2C,D and Figure 3C). Furthermore, increased sub-G1 signals by FACS
and increased caspase 3/7 activity were observed for A375 treated with combinations than for signal
agent treatment, indicating more apoptosis was induced by the combination treatments (Figure 2E,F).
This was compatible with increased p53 target transcripts (Figure 2B). Consistent with our previous
report [9], there was no significant induction of apoptotic biomarkers, such as sub-G1 signals on FACS
analysis or caspase 3/7 activity, in the WM35 cell line (Figure 3D,E).
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Figure 2. Trametinib and MDM2 inhibitor combination induction of p53 transcriptional targets 
resulting in enhanced cell cycle arrest and apoptosis of A375 cells. Analysis of A375 cells treated with 
Figure 2. Trametinib and MDM2 inhibitor combination induction of p53 transcriptional targets resulting
in enhanced cell cycle arrest and apoptosis of A375 cells. Analysis of A375 cells treated with nutlin-3
(1 µM)/RG7388(0.2 µM) ± trametinib (1 nM) for the indicated times, by immunoblotting (A), qRT-PCR
(B), for cell cycle distribution changes (C,D), FACS sub-G1 signals (E), caspase 3/7 activity (F). *, p < 0.05.
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Figure 3. Trametinib and MDM2 inhibitor combination treatments in paired WM35 (p53WT)/WM35-R 
(p53MUT). Cells treated with RG7388 (0.2 µM) ± trametinib (1 nM) for indicated times and analyzed by 
immunoblotting (A) and qRT-PCR (B), by FACS analysis for cell cycle distribution changes (C) and 
sub-G1 events (D), and for caspase 3/7 activity (E). hrs, hours. 
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Figure 3. Trametinib and MDM2 inhibitor combination treatments in paired WM35 (p53WT)/WM35-R
(p53MUT). Cells treated with RG7388 (0.2 µM) ± tr metinib (1 nM) for indicated times and analyzed by
immunoblotting (A) and qRT-PCR (B), by FACS analysis for cell cycle distribution ch ges (C) and
sub-G1 events (D), and for caspase 3/7 activity (E). hrs, hours.
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2.3. The Combination Effects for Trametinib and MDM2 Inhibitors in Paired WM35/WM35-R Cell Lines
The combination effects were also explored in WM35-R [9], a p53 mutated (p53MUT, Gly334Val)
cell line, selected from WM35 (Figure 3). Although the WM35-R cells remained responsive to trametinib
(1 nM), there were no significant differences with and without the addition of RG7388 (0.2 µM) on
protein responses (Figure 3A), transcripts (Figure 3B), or cell cycle distribution (Figure 3C,D), and
only the effects of trametinib could be found in WM35-R treated with combination of trametinib and
RG7388, indicating RG7388 played no role in the response of WM35-R, suggesting that the effects of
combination seen in the p53WT WM35 and A375 are p53 dependent.
2.4. DUSP6 Regulation by pERK Rather Than p53
DUSP6, a phosphatase which acts on pERK, was also reported to be regulated by p53 and MAPK
activity. Therefore, DUSP6 is a likely key candidate protein for involvement in connecting p53 and
MAPK pathways, and could be important in the mechanism of synergy seen for combination treatment
with MDM2 and MEK inhibitors. To examine whether DUSP6 is indeed regulated by p53 or pERK,
A375 and WM35 were treated with MDM2 inhibitors or trametinib separately. There were no significant
changes of DUSP6 protein and mRNA in either cell line treated with nutlin-3 or RG7388 (Figure 4A–C).
However, significant dose-dependent suppression of DUSP6 was found after trametinib treatment
(Figure 4D–F) and the decrease of DUSP6 occurred at an early time point of 2–4 h following pERK
suppression (Supplementary Figure S3A). DUSP6 suppression was also found in A375 treated with the
BRAF inhibitor, vemurafenib, offering additional evidence to support the observation that inhibition
of MAPK activity suppresses DUSP6 (Supplementary Figure S3B). Therefore, we conclude that DUSP6
is regulated by MAPK activity but not by p53, at least in A375 and WM35 melanoma cells.
In addition, immunoblotting of WM35, following treatment with a combination of RG7388 and
trametinib for 6 and 24 h, shows DUSP6 suppression to be associated with reduced phosphorylation
of pERK (Figure 4G). Phospho-p53 (S15) was probed, as serine 15 is an important key residue in
the post-translational modification of p53 [26]. The combination treatment with MEK and RG7388
inhibitors induced more phospho-p53 after 24 h than RG7388 alone, consistent with the hypothesis
that DUSP6 suppression increases p53 phosphorylation. Similar results were found for A375 treated
with trametinib and HDM201 (Supplementary Figure S4). Even though p53 phosphorylation status
was increased in association with downregulation of DUSP6, it was not clear whether this is a direct or
indirect effect of DUSP6 on p53 phosphorylation. It has been reported that phospho-ATM increases
when DUSP6 is suppressed [27]. Since ATM phosphorylates p53, we further hypothesized that this
may represent an indirect route for DUSP6 to regulate p53 phosphorylation via ATM.
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Figure 4. DUSP6 was regulated by pER and not by p53. ( ) I unoblotting of A375 treated with
nutlin-3 (5 µM) and RG7388 (1 µM) for 6 h. (B) Immunoblotting of WM35 treated with RG7388 (0.2
and 1 µM) for 6 h. (C) DUSP6 mRNA in A375 and WM35 treate with the indicated concentrations of
nutlin-3 and RG7388 for 6 h, measured by qRT-PCR. (D,E) Immunoblotting of A375 (D) and WM35
(E) treated with trametinib for the indicated concentrations a times. (F) Changes of DUSP6 mRNA
by qRT-PCR in WM35 treated with trameti ib. (G) Immunoblotting of WM35 treated with trametinib
(1 n ) and/or RG7388 (0.2 µM) for 6 and 24 h. TRA, trametinib.
2.5. DUSP6 Suppression by siRNA Promotes the Effect of MDM2 Inhibitors through ATM-Mediated
p53 Phosphorylation
To investigate the causal link between DUSP6 suppression y tr metinib and i creased p53
phosphorylatio and its activity, tra sient knockdown of DUSP6 by two alternative siRNA was performed.
Both A375 and WM35 were transfected with 40 nM DUSP6 siRNA for 24 h followed by treatment with
MDM2 inhibitors, RG7388 or HDM201, for the indicated times. DUSP6 suppression by two alternative
siRNA made both A375 and WM35 cell lines more sensitive to either RG7388 or HDM201 (Figure 5A–D).
Immunoblotting of WM35 after siRNA-mediated DUSP6 knockdown followed by HDM201 treatment for 6
and 24 h demonstrated that higher levels of p53 phosphorylation (Ser15) and more induction of p21 and
MDM2 occurred after DUSP6 suppression (Figure 5E). Similar results were found with A375 after siRNA
knockdown and HDM201 treatment (Supplementary Figure S5A). Interestingly, pERK, a reported substrate
of DUSP6, did not increase appreciably after DUSP6 suppression, possibly because of compensation by
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phosphatase activity from other DUSP family members [27], and/or pERK may be saturated by upstream
kinases activated by the BRAF mutation.
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Figure 5. DUSP6 suppres ion by siR r i ibitors through
ATM-mediated p53 phosphorylation. ( ) , ) 35 (C,D) after
24-h treatm n with siRNA against DUSP6 followed by 48-h RG7388 (A,C) or HDM201 (B,D) treatment.
(E) Im unoblotting of WM35 after siRNA knockdown of DUSP6 f r 24 h foll wed by treatment with
1 µM HDM201 for 6 and 24 h. (F) Immunoblotting of WM35 after 24-h DUSP6 siRNA knockdown,
followed by 200nM RG7388 ± 10 µM KU55933 24-h treatment. (G,H) Flow cytometry of A375 treated
with DUSP6 siRNA followed by H M201 addition and presented as a histogram (G) and % of sub-G1
signals (H). (I) Caspase 3/7 assay of A375 after 24-h DUSP6 iRNA followed by RG7388 or HDM201
treatment with the indicated doses. hrs, hours; *, p < 0.05.
The ATM inhibitor KU55933 was used to evaluate whether the DUSP6 regulation of phospho-p53
is ATM dependent. Immunobl tting of WM35 (Figure 5F) and A375 ( Figure S5B)
treated with RG738 after si - e i t the increased phospho-ATM
(S1981) and phospho-p53 ere reverse t i icates that USP6
inhibit on by siRNA promotes p53 phosphorylation mainly through ATM, rather than by a direct effect
on p53.
Significant increases in apoptosis induced by HDM201 after siRNA-mediated DUSP6 knockdown
were also evident from sub-G1 signal by FACS analysis (Figure 5G,H, Supplementary Figures S6 nd
S7) and caspase 3/7 ctivity (Figure 5I). Thes observations re eal DUSP6 to be a negative regulator
of p53 and, hence, a potential therapeutic target for potentiating the effect of MDM2 inhibitors in
cutaneous melanoma.
2.6. DUSP6 Enzymatic Inhibitor (BCI) at a ose it i cer ffect of
MDM2 Inhibitors through p53 Phosphorylation
To further explore the role and potential tar eti f - i t ative regulatory
signaling from the MAPkinase path ay to i , selective s a l molecule
inhibitor of DUSP6, 2-benzylidene-3-(cyclohexylamino)-1-inda one hydrochloride (BCI) which in ibits
DUSP6 allosterica ly [28,29]. The GI50 values of BCI for A375 and WM35 were 1.38 + 0.24 µM and
3.17 ± 0.21 µM respectiv ly (Supplementary Figure S8). Since BCI was reporte hole
organism toxicity at c r t an 5 µ [30], BCI concentrations lower than the GI50
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(1 µM for A375, 3 µM for WM35), with minimal effect on cell proliferation, were used for combination
treatment with HDM201 and showed potentiation of HDM201 treatment (Figure 6A,B), which was
consistent with the results of siRNA-mediated DUSP6 suppression. To examine whether the effects of
potentiation are due to ATM-dependent p53 phosphorylation, immunoblotting of A375 treated with
1 µM HDM201 ± 1 µM BCI ± ATM inhibitor for 6, 24 h was performed (Figure 6C). BCI alone did
not show any effects on p53 and its phosphorylation (Ser15), whereas increased p53 phosphorylation
at Ser15 was found after HDM201 and BCI combination treatment compared with HDM201 alone.
Furthermore, the increased phosphorylation was completely reversed by the KU55933 ATM inhibitor,
indicating DUSP6 inhibition by BCI promotes p53 phosphorylation mainly through ATM, rather than
a direct effect on p53.
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3. Discussion
In the current study, combined targeting of the MAPK and p53 pathways by trametinib and
MDM2 inhibitors was found to be synergistic and to involve DUSP6 suppression by trametinib,
followed by increased p53 phosphorylation. DUSP6 was shown to be regulated by ERK, rather
than p53, and downregulation of DUSP6 by trametinib treatment resulted in reduced phosphatase
activity on ATM and a consequent increase in p53 (Ser15) phosphorylation, after p53 activation
by combined treatment with MDM2 inhibitors (nutlin-3/RG7388/HDM201) in BRAFV600E/p53WT
cutaneous melanoma cells. These changes promoted the growth-inhibitory and cytotoxic activity
of p53 by increasing p53-dependent transcriptional activity (Figure 7). DUSP6 suppression by both
siRNA knockdown of expression and enzymatic inhibition (BCI) showed similar enhancement of
MDM2 inhibitor activity.
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with MDM2 inhibitors. DUSP6 is regulated by ERK rather than p53. Downregulation of DUSP6
by MEK inhibition with trametinib results in loss of DUSP6 phosphatase activity on ATM and
consequent increased ATM-mediated phosphorylation of p53 after p53 release by MDM2 inhibitors
(nutlin-3/RG7388/HDM201) in BRAFV600E/p53WT cutaneous melanoma cells. These changes, leading
to increased p53 phosphorylation, promote the growth-inhibitory and cytotoxic activity of p53 by
increasing p53-dependent transcriptional activity.
The effects of DUSP6 inhibition by trametinib, in the current study, were consistent with
knockdown of DUSP6 expression by siRNA and direct enzymatic inhibition with BCI. All showed
similar trends when combined with MDM2 inhibitors, except the time scales differed. The responses
were evaluated at two different time points, 6 and 24 h. The early effects of enhanced p53
phosphorylation and activity were found after 6-h treatment with MDM2 inhibitors when DUSP6 was
suppressed by siRNA or BCI (Figures 4E and 6C), but not at this early time point, when DUSP6 was
suppressed by trametinib (Figure 4G and Supplementary Figure S4). By contrast, the phosphorylation
of p53 and induction of its transcriptional targets were particularly evident after 24-h combined trametinib
and MDM2 inhibitor treatments. This may be due to the difference between trametinib and siRNA/BCI
suppression of DUSP6, in that trametinib additionally suppresses pERK, which has been reported to be a
direct kinase of p53, for instance, phosphorylating serine 15 in response to UV radiation [31]. Therefore, a
balance between pERK and DUSP6 plausibly determines the p53 phosphorylation status. In addition,
DUSP6 is not the only phosphatase which works on ATM/p53. Other phosphatases, such as WIP1, a
direct transcriptional target of p53, can also contribute to negative regulation of p53 phosphorylation,
although this was ruled out as a contributory factor in the mechanism of synergy between trametinib and
MDM2 inhibitors in this study (Supplementary Figure S4).
Our observation of synergy is supported by a previous limited study using nutlin-3 (early
tool MDM2 inhibitor) and two MEK inhibitors, U0126 (used as a research tool compound only)
and AZD6244 (under clinical trials) [32]. However, no advanced mechanistic experiments and
explanations were addressed in the previous study. Some possible explanations were discussed [33],
and one plausible explanation is that MEK inhibition by U0126 initiated downregulation of the MDM2
mRNA and protein, followed by increased p53 activity [34]. However, such a pattern was not found
in our study (Figure 2A,B and Figure 3A,B). We investigated the combination with trametinib, a
clinically approved compound, and MDM2 inhibitors, nutlin-3/RG7388/HDM201 (the latter two are
in clinical trials) in melanoma cell lines, which has direct translational implications to the clinical
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setting. In addition, our detailed study revealed a novel mechanism, which involves DUSP6 and p53
phosphorylation mediated by ATM, offering another potential therapeutic strategy for enhancing
non-genotoxic p53 reactivation by MDM2 inhibitors.
Combination and dose reduction index values were used to evaluate the synergism and dose
reduction potential of these combinations [25]. Favorable dose reductions (DRI > 1.0) (Table 1)
for the combination of trametinib and MDM2 inhibitors implies this combination can reduce the
individual drug dose to reach the same therapeutic effect as higher individual doses, leading to
decreased side effects compared with the single agents, since they have differing dose-limiting toxicities.
In the case of MDM2 inhibitors, the dose-limiting toxicities are hematological (neutropenia and
thrombocytopenia [17,35], whereas for trametinib, the dose-limiting toxic effects include rash, diarrhea,
and central serous retinopathy [36].
In addition to providing a mechanistic insight into the synergistic effects of trametinib and
MDM2 inhibitors, DUSP6, as a negative regulator of ATM/p53, was identified as a potential
therapeutic target for enhancing the effect of p53 activators. DUSP6 expression in cutaneous
melanoma is the highest among all cancer cell lines and the second highest among cancer tissue
types (Supplementary Figure S1), suggesting DUSP6 plays a particularly important role in cutaneous
melanoma. Consistent with previous studies reporting DUSP6 regulation of the DNA damage response
pathway, in which DUSP6 suppression was associated with elevated levels of phosphorylated H2AX,
ATM, and CHEK2, [27] we found that DUSP6 regulated p53 phosphorylation via ATM, even when
p53 is released and activated by MDM2 inhibitors in a non-genotoxic manner.
We failed to find obvious changes of DUSP6 expression after activation of p53 by MDM2 inhibitors
in melanoma cell lines, despite clear induction of p53 and a previous suggestion of DUSP6 as a p53
direct transcriptional target [18]. This previous study reported the identification of two putative
p53 binding half-sites in the DUSP6 promoter region and chromatin immunoprecipitation (ChIP)
analysis to support direct p53 binding to the DUSP6 promoter [18]. However, global analysis of p53
transcription-factor binding sites by ChIP with the paired-end ditag (PET) sequencing strategy did not
identify DUSP6 as a transcriptional target [37]. Furthermore, none of the 16 datasets extracted from 13
genome-wide studies identify DUSP6 as a transcriptional target of p53 [38]. These collective lines of
evidence did not support DUSP6 being a p53 direct transcriptional target, and is more consistent with
the lack of induced DUSP6 expression by MDM2 inhibitors, alone, in our study.
In this study, the indirect regulation of p53 phosphorylation by DUSP6 via ATM is evidenced
by the results of DUSP6 suppression using three different methods (MEK inhibitor, DUSP6 siRNA,
and DUSP6 inhibitor). Phospho-p53 (S15) was induced more after MDM2 treatment under DUSP6
suppression than without DUSP6 suppression. In addition, we also probed phospho-ATM (S1981),
which showed induction under DUSP6 suppression. Furthermore, the ATM inhibitor, KU55933, was
used to reverse the increases in phospho-p53 and phospho-ATM, which demonstrated that these
increases in phospho-p53 and phospho-ATM were ATM-dependent.
4. Materials and Methods
4.1. Cell Lines and Reagents
A375 (p53WT), and paired WM35 (p53WT)/WM35-R (p53MUT) cutaneous melanoma cell lines [9]
were used in the study and were routinely cultured using Dulbecco’s modified Eagle’s medium
(DMEM) medium, which was supplemented with 10% (v/v) fetal calf serum. All the cell lines were
authenticated by serial tandem repeat (STR) profiling (NewGene, Newcastle, UK). Nutlin-3 was
purchased from NewChem (Newcastle, UK), and RG7388 and HDM201 were sourced by custom
synthesis (Astex Pharmaceuticals, Cambridge, UK). Trametinib and vemurafenib were purchased
from Cambridge Bioscience (Cambridge, UK). All compounds were initially dissolved in dimethyl
sulfoxide (DMSO) (Sigma-Aldrich, Gillingham, UK) and used at a final concentration of 0.5% DMSO,
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optimized to give minimal cytotoxic effects on cells, and 0.5% DMSO solvent controls were included
in all experiments.
4.2. Growth Inhibition and Clonogenic Survival Assays
For growth inhibition studies, cells were seeded in 96-well plates overnight, and treated with
indicated drugs for 72 h. The cells were fixed using Carnoy’s fixative followed by sulforhodamine B
(SRB) staining and quantification, as previously described [9,39]. For clonogenic survival, cells were
seeded in 6-well plates overnight, and treated with indicated drugs for 72 h. Fresh medium was
replaced, and the cells were fixed and stained with crystal violet when visible colonies formed [40].
4.3. Combination Treatment
The effect of MDM2 inhibitors, nutlin-3/RG7388/HDM201, in combination with trametinib,
was investigated for two BRAFV600E and p53WT melanoma cancer cell lines using median-effect
analysis [25]. The growth inhibition of these cell lines was determined after 72 h exposure to nutlin-3,
RG7388, HDM201, or trametinib, and in combination at five concentrations and a constant ratio, with
a range covering their respective GI50 concentrations.
To determine whether the differences in response for growth inhibition were synergistic, additive
or antagonistic, the data were analyzed using median-effect analysis, and CI and DRI values were
calculated using CalcuSyn (Biosoft, Ferguson, MO, USA). CI values for each constant ratio combination
and at effect levels of ED50, ED75, ED90, and ED95 were computed.
4.4. Immunoblotting
Cells lysates were harvested by 2% SDS lysis buffer, heated and sonicated. The protein
concentrations of the cell lysates were estimated using a Pierce® BCA Protein Assay kit. The detailed
protocol used for immunoblotting can be found in our previous report [9]. The primary and
secondary antibodies used in the current study were listed as follows: p53 (DO-7) (#M7001,
Dako, Glostrup, Denmark), MDM2 (Ab-1) (#OP46, Merck Millipore, Watford, UK), p21WAF1 (EA10)
(#OP64, Calbiochem (Millipore, Watford, Herts, UK), p-ERK (E-4) (#sc-7383, Santa Cruz, Dallas,
TX, USA), ERK (K-23) (#sc-94, Santa Cruz), GAPDH (14C10) (#2118, Cell Signaling Technology,
Danvers, MA, USA), WIP1 (F-10) (#sc-376257, Santa Cruz Biotechnology), phospho-p53 (S15) (ab1431,
Abcam, Cambridge, UK), phospho-ATM(S1981) (#AF1655, R&D systems, Abingdon, UK), actin
(#A4700, Sigma-Aldrich), secondary goat anti-mouse/rabbit horseradish peroxidase (HRP)-conjugated
antibodies (#P0447/P0448, Dako).
4.5. RNA Extraction and qRT-PCR
Cells were treated with the indicated drugs for the indicated times and then were collected for
RNA extraction, reverse transcription, and qRT-PCR. The detailed protocol and analysis method was
reported in our previous publication [9].
The primers used in current study: MDM2(NM_002392): F—AGTAGCAGTGAATCTACAGGGA,
R—CTGATCCAACCAATCACCTGAAT; CDKN1A(NM_000389): F—TGTCCGTCAGAACCCATGC,
R—AAAGTCGAAGTTCCATCGCTC; BBC3(PUMA)(NM_001127240): F—ACCTCAACGCACAGTA
CGA, R—CTGGGTAAGGGCAGGAGTC; BAX(NM_001291428): F—CCCGAGAGGTCTTTTTCCGAG,
R—CCAGCCCATGATGGTTCTGAT; TP53I3(PIG-3)(NM_004881): F—AGCGAGGAAGTCTGATCACC,
R—CGTGGAGAAGTGAGGCAGAA; TP53(NM_000546) F—CAGCACATGACGGAGGTTGT,
R—TCATCCAAATACTCCACACGC; GAPDH (NM_002046): F—CAATGACCCCTTCATTGACC, R—G
ATCTCGCTCCTGGAAGAT.
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4.6. Fluorescence-Activated Cell Sorting (FACS)
Cells were treated with the indicated drugs for the indicated times and all floating and adhered
cells were collected and fixed by 70% cold ethanol for staining by propidium iodide (Sigma-Aldrich,
Dorset, UK). Detailed materials can be found in our previous report [9].
4.7. Caspase 3/7 Activity Assay
Melanoma cells were seeded in white 96-well plates (Greiner Bio-One, Stonehouse, Glos, UK) and
treated after 24 h. Caspase-3/7 enzymatic activities were measured using a FLUOstar Omega plate
reader (BMG Labtech, Aylesbury, UK) after adding a 1:1 ratio of CaspaseGlo 3/7 reagent (Promega,
Southampton, UK) to growth media and incubating for 30 min. All values were expressed as a ratio of
signal relative to solvent control.
4.8. SiRNAs and Transfection
A final concentration of 40nM siRNA duplex (Eurogentec, Hampshire, UK) against
DUSP6 and control noncoding sequence was used for transfection with Lipofectamine
2000 (Thermo Fisher Scientific) in Opti-MEM Reduced Serum Media (Thermo Fisher
Scientific). The sequences were designed as follows: Control SiRNA (SiControl), sense:
5′-GCGCGCUUUGUAGGAUUCGdTdT-3′, antisense: 5′-CGAAUCCUACAAAGCGCGCdTdT-3′;
two alternative DUSP6 targeted siRNA (SiDUSP6, NM_001946), SiDUSP6 #1, sense: 5′-
UAGCACGGAGUCCGAAUUAAU dTdT-3′, antisense: 5′-AUUAAUUCGGACUCCGUGCUA
dTdT-3′, SiDUSP6 #2, sense: 5′-UACGGACACUAUUAUCACUAAdTdT-3′, antisense:
5′-UUAGUGAUAAUAGUGUCCGUAdTdT-3′.
4.9. Statistical Analysis
Data were presented as mean ± standard error of the mean (SEM) unless otherwise stated.
Statistical tests were carried out using GraphPad Prism 6 software and all p-values represent
paired t-tests of at least three independent repeats. A p-value less than 0.05 was considered as
statistically significant.
5. Conclusions
In summary, we report the novel finding that MDM2 inhibition effectively activates p53 function
and synergizes with trametinib as a result of increased p53 phosphorylation via trametinib-induced
reduction in DUSP6 expression. Furthermore, this involves an indirect ATM-dependent step.
The lower DUSP6 levels induced by trametinib inhibition of MEK result in increased phosphorylated
ATM levels which, in turn, results in increased ATM-dependent p53 phosphorylation (Figure 7).
These results have direct clinical implications and indicate potential ways of improving the efficacy of
current targeted treatment with MAPK pathway inhibitors in BRAFV600E, p53WT melanoma.
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trametinib, RG7388 and HDM201 for 72 h, Figure S3: Immunoblotting of A375 and WM35 treated with trametinib
or vemurafenib, Figure S4: Immunoblotting of A375 cells treated with trametinib, HDM201, or combinations of
the two compounds for 6 and 24 h, Figure S5: Immunoblotting of A375 after DUSP6 siRNA knockdown, followed
by 200 nM RG7388 ± 10 µM KU55933, Figure S6: Cell cycle distribution (A–D) and Sub-G1 phase (E) of A375 cells
after treatment with two siRNA against DUSP6 for 24 h, followed by HDM201 addition for 24 and 48 h, Figure
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